Audit: QRS - Oxytocin for Health & Longevity

Audit conducted on 07/08/2026 20:51 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All benefit/risk tier items match ER section headings; protocol values (24 IU, 8–40 IU, 10–24 IU, 10–12 IU, 2–3× weekly, morning, 45 min/30 min anchors) trace to ER lines 429, 437, 439, 447, 462; all 12 monitoring targets match the ER table at lines 512–523.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	At-a-glance mirrors the ER Conclusion hedges (“mostly vanish”, “without weight loss”, “no reliable pain relief”, “watching people, not treating them”); time_3_sub keeps “if at all” from ER line 484.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications from ER lines 362, 370, 388, 392–399 remain in the STOP gate; caution-severity interactions remain in the caution gate. No directional shift found.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Every gate item originates in the ER Key Interactions & Contraindications section; nothing from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or the risk card.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs or expert names in the QRS. All named drugs (desmopressin, terlipressin, misoprostol, dinoprostone, methylergonovine, sertraline, escitalopram, venlafaxine, duloxetine, hydrochlorothiazide, chlorthalidone, indapamide, carbamazepine, oxcarbazepine, pseudoephedrine, phenylephrine, ondansetron, azithromycin, sotalol, ibuprofen, naproxen, diclofenac, oxymetazoline, xylometazoline, diphenhydramine, doxylamine, chlorobutanol) appear in the same ER bullets.
1.6	The QRS does not introduce new attributions.	🟢	No laboratory, practitioner, company or author is named anywhere in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Detached, evidence-weighted register carried through from the ER, including its scepticism about the behavioral literature.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and tiered evidence grades alongside plain-language at-a-glance framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe the research/practitioner convention (“De facto research standard”, “The research convention”) rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a user; footer disclaimer retained from the template.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of “recommend”, “advise”, “should” addressed to a user.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical shorthand is confined to the decision gates and monitoring table, where thresholds and drug classes must be preserved under items 8.5/9.5; the at-a-glance and qualitative sections are plain.
2.8	Information is presented in a concise and very compact manner	🟢	Single-clause list entries throughout; no elaborations or mechanistic rationale carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to test sodium, source a compounded product and run scheduled off-cycles.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Cycling schedule, twelve-marker monitoring panel and off-cycle verification all assume effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a general-population reader; contraindication thresholds are given numerically.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the fact that only the licensed obstetric use is strongly supported, which is the decision-relevant signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“intravenous dosing”, “intranasal”, “hypersensitivity”, “hyponatremia” used throughout; “grey-market” and “nuisance effects” are the ER’s own terms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and column headers are byte-identical to [qrs_template].
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# spans are instantiated as marker_1..12 and qualitative_item_1..6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable <span website="evidence_review">, <span website="audit"> and <span website="full_review"> elements are unchanged from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Qualitative items carry the ER’s bold labels verbatim (“Appetite and eating behavior”, “Stress reactivity”, “Social warmth and irritability”, “Sleep onset and continuity”, “Training recovery”, “Nasal comfort”); monitoring row labels are the ER biomarker names verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label drawn from an ER bulleted item has been altered.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to single-clause entries rather than reproduced at ER length; the template’s A4 print rules are intact.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no value is echoed into the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: oxytocin_2026-0807-1741_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0807-2022.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: oxytocin_2026-0807-1741_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys plus git_user and git_issue; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Oxytocin for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Oxytocin for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/07/2026”, matching qrs_creation_date 2026-0807.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Each clause maps to ER Conclusion lines 562–566.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Seventy years / cheap → line 562; licensed use only → 564; small effects, appetite without weight loss, no pain relief → 564; bone observational → 564; sex divergence → 566.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “childbirth”, “nasal spray”, “bone findings” are lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items trace to ER lines 362, 370, 388 and 392–399.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight “Populations who should avoid this intervention” bullets plus the three absolute-contraindication agents (antidiuretics, MDMA, prostaglandins/ergot alkaloids).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No trailing dash clauses; the only en-dash is inside the “NYHA III–IV” range. Mechanistic rationale from the ER bullets was dropped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	135 mmol/L, 30 mL/min/1.73 m², NYHA III–IV, “within the preceding two years”, “at any gestational age”, “under 18”, and the drug exemplars are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	Contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items trace to the ER bullets at lines 364–388.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The three absolute-contraindication entries (antidiuretics, prostaglandins/ergot alkaloids, MDMA) appear only in the STOP gate and are not duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Twelve <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Class name plus exemplars only; every Severity/Clinical consequence/Mitigation clause was stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Each class retains its ER exemplar drugs, trimmed to fit (e.g., QT-prolonging keeps ondansetron, azithromycin, sotalol).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses.
9.7	If no [caution_items] are present the section is left empty	N/A	Key interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Values and sublines trace to ER Therapeutic Protocol lines 429, 437, 439, 447 and to Discontinuation & Cycling line 462.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Frequency and Timing; route is folded into the dose value (“24 IU intranasal”).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects, and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Appetite, stress response and structural change — the only three timelines given in the ER (line 484).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Appetite (Medium, SMD −0.66) precedes stress response (Medium, Hedges g −0.43), which precedes structural change (Speculative).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated from ER lines 196 and 484.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information under Practical Considerations.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every entry corresponds to an ER Expected Benefits sub-heading.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 521–532).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; all Magnitude lines and “⚠️ Conflicted” qualifiers dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“Through a Brain-Liver Axis” and “in Models of” style mechanistic tails were reduced; no parenthetical content carried over.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four evidence tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every entry corresponds to an ER Potential Risks & Side Effects sub-heading (lines 278–342).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 583–594).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only; the 14.3%/9.0%/7.2% frequencies and QTc/mmHg magnitudes were dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over into any tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER Monitoring Protocol & Defining Success biomarker table (lines 510–523).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER rows present in ER order, with names and optimal ranges verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 746 condenses ER line 525 (two and six weeks, three-to-six-monthly, four weeks after dose increase, first three doses, six-monthly, twelve-to-twenty-four-monthly).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER qualitative marker list at lines 529–534.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present, with the ER’s bold labels verbatim.

Issues 07/08/2026 20:51

Pass rate 100.00%. No issues found.

Issues 07/08/2026 20:46

1. 4.3 — Monitoring labels abbreviated: Three marker_#_name labels abbreviate the ER’s biomarker names instead of using them as written — QRS line 634 “eGFR” vs ER line 514 “Estimated glomerular filtration rate”, QRS line 678 “Bone mineral density (DXA)” vs ER line 518 “Bone mineral density by dual-energy X-ray absorptiometry”, and QRS line 689 “hs-CRP” vs ER line 519 “High-sensitivity C-reactive protein”.

Fixes 07/08/2026 20:46

1. 4.3 — Monitoring labels abbreviated: Restored the ER’s biomarker names verbatim in the Monitoring table — “eGFR” to “Estimated glomerular filtration rate”, “Bone mineral density (DXA)” to “Bone mineral density by dual-energy X-ray absorptiometry”, and “hs-CRP” to “High-sensitivity C-reactive protein”.

Issues 07/08/2026 20:39

1. 4.5 — Sheet exceeds one A4 page: The QRS carries roughly 7,000 characters of visible text; at the template’s print metrics the decision gates (11 + 12 items), the twelve-row Monitoring table and the six multi-line Qualitative items lay out to approximately twice the 774 pt one-page budget, so no section was condensed to its per-section budget.
2. 9.5 — Magnesium example list dropped: The caution item “Magnesium supplements and magnesium sulfate” drops the ER’s parenthetical example list “(magnesium glycinate, citrate, L-Threonate)” (ER line 382) entirely instead of trimming it, while every other caution item preserves its parenthetical.

Fixes 07/08/2026 20:39

1. 9.5 — Magnesium example list restored: Changed the caution item to “Magnesium supplements (glycinate, citrate, L-threonate) and magnesium sulfate”, restoring the ER’s parenthetical example list (ER line 382) in trimmed form.
2. 4.5 — Contraindications condensed: Shortened eight of the eleven stop items (e.g. “Heart failure NYHA Class III or IV, or any decompensated fluid-overload state” → “Heart failure NYHA III–IV, or decompensated fluid overload”; “Vasopressin analogues and other antidiuretic agents (…)” → “Antidiuretic agents (…)”), keeping every threshold, time window and drug example.
3. 4.5 — Key Interactions condensed: Trimmed redundant class wording from six caution items (e.g. “Over-the-counter nonsteroidal anti-inflammatory drugs” → “NSAIDs”; “Carbamazepine, oxcarbazepine and other hyponatremia-associated antiepileptics” → “Hyponatremia-associated antiepileptics (carbamazepine, oxcarbazepine)”).
4. 4.5 — Protocol and Time-to-Effect subs shortened: Reduced action_1_sub, action_2_sub, action_3_sub and time_3_sub by roughly a line each while preserving the studied range, cycling pattern, effect-window timings and the “if at all” caveat.
5. 4.5 — Benefits and Risks entries tightened: Condensed benefits_speculative, risks_high, risks_low and risks_speculative (e.g. “extension of remaining lifespan in combination with a fibrosis-pathway inhibitor” → “lifespan extension with a fibrosis-pathway inhibitor”), with all tier items retained.
6. 4.5 — Monitoring table compacted: Replaced three long marker names with the ER’s own abbreviations (eGFR, Bone mineral density (DXA), hs-CRP), shortened four rationale cells, and trimmed the cadence line; all twelve biomarkers and their targets are unchanged.
7. 4.5 — Qualitative Assessment shortened: Trimmed four of the six item descriptions to a single line each, leaving all six bold labels verbatim from the ER.

Issues 07/08/2026 20:29

1. 4.5 — Sheet exceeds one A4 page: The populated sheet renders well beyond a single A4 page; the largest contributors are the ~460-character monitoring_cadence (line 746), the five multi-line qualitative_item_* entries carrying their full ER rationale clauses (lines 755–770), and the ~160-character action_1_sub (line 450), stacked on top of 11 contraindications, 12 interactions and a 12-row marker table.

Fixes 07/08/2026 20:29

1. 4.5 — Monitoring cadence condensed: Shortened monitoring_cadence from ~440 to ~330 characters, dropping the redundant “while dosing continues”, “and thereafter only if symptoms occur” and “no more often than” clauses while keeping every interval.
2. 4.5 — Qualitative entries condensed: Trimmed the rationale tails on qualitative_item_1/2/3/5/6 (e.g. “both directions matter, since increased irritability is a documented effect and is the commonest reason people stop” → “both directions matter; irritability is the commonest reason people stop”); all six bold labels kept verbatim.
3. 4.5 — Protocol sub-lines condensed: Shortened action_1_sub (“De facto standard across the behavioral and metabolic literature” → “De facto standard in the literature”), action_2_sub (“Rather than the daily or four-times-daily schedules used in psychiatric trials” → “Not the daily schedules of psychiatric trials”) and action_3_sub (“The convention in the research literature” → “The research convention”).
4. 4.5 — Interaction item shortened: Rewrote the antiepileptics caution item as “Carbamazepine, oxcarbazepine and other hyponatremia-associated antiepileptics” to drop it to a single rendered line.